• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Optimal Treatment of Stage IIIA-N2 Non-Small Cell Lung Cancer: A Neverending Story?

作者信息

Van Schil Paul E

机构信息

Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Antwerp, Belgium.

出版信息

J Thorac Oncol. 2017 Sep;12(9):1338-1340. doi: 10.1016/j.jtho.2017.07.001.

DOI:10.1016/j.jtho.2017.07.001
PMID:28838709
Abstract
摘要

相似文献

1
Optimal Treatment of Stage IIIA-N2 Non-Small Cell Lung Cancer: A Neverending Story?ⅢA-N2期非小细胞肺癌的最佳治疗：一个永无止境的故事？
J Thorac Oncol. 2017 Sep;12(9):1338-1340. doi: 10.1016/j.jtho.2017.07.001.
2
Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.III A-N2期非小细胞肺癌根治性切除术后转移pN2淋巴结数量的预后意义
Clin Lung Cancer. 2015 Nov;16(6):e203-12. doi: 10.1016/j.cllc.2015.04.004. Epub 2015 Apr 23.
3
Management of patients with resectable stage IIIA (N2) NSCLC.可切除的IIIA期（N2）非小细胞肺癌患者的管理
J Surg Oncol. 2006 Dec 1;94(7):551-2. doi: 10.1002/jso.20649.
4
Mortality associated with pneumonectomy after induction chemoradiation versus chemotherapy alone in stage IIIA-N2 non-small cell lung cancer.IIIA-N2期非小细胞肺癌诱导放化疗与单纯化疗后肺切除相关的死亡率
J Thorac Cardiovasc Surg. 2008 Mar;135(3):718; author reply 718-9. doi: 10.1016/j.jtcvs.2007.10.052.
5
Validation of pN2 sub-classifications in patients with pathological stage IIIA N2 non-small cell lung cancer.病理分期为IIIA期N2非小细胞肺癌患者中pN2亚分类的验证
Interact Cardiovasc Thorac Surg. 2011 May;12(5):733-8. doi: 10.1510/icvts.2010.249896. Epub 2011 Feb 5.
6
A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209).一项针对IIIA期N2非小细胞肺癌患者比较诱导化疗后手术与单纯手术的随机试验（JCOG 9209）。
J Thorac Cardiovasc Surg. 2003 Feb;125(2):254-60. doi: 10.1067/mtc.2003.15.
7
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).诱导化疗和同期放化疗后可切除 IIIA(N2)和部分 IIIB 期非小细胞肺癌患者的手术与根治性同期放化疗增敏的 III 期研究（ESPATUE）
J Clin Oncol. 2015 Dec 10;33(35):4194-201. doi: 10.1200/JCO.2015.62.6812. Epub 2015 Nov 2.
8
The Underrated Effect of Neoadjuvant Therapy Before Pneumonectomy for Stage IIIA Non-Small Cell Lung Cancer.新辅助治疗对ⅢA期非小细胞肺癌肺叶切除术前的潜在影响
Ann Thorac Surg. 2016 Sep;102(3):1030. doi: 10.1016/j.athoracsur.2016.02.102.
9
Surgical approach to locally advanced non-small cell lung cancer.局部晚期非小细胞肺癌的手术治疗方法。
Cancer J. 2013 May-Jun;19(3):217-21. doi: 10.1097/PPO.0b013e318299f647.
10
Management of stage IIIA (N2) non-small cell lung cancer: A transatlantic perspective.ⅢA期（N2）非小细胞肺癌的治疗：跨大西洋视角
J Thorac Cardiovasc Surg. 2016 May;151(5):1235-8. doi: 10.1016/j.jtcvs.2016.01.035. Epub 2016 Mar 17.

引用本文的文献

1
Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.PACIFIC 试验的探索性分析：放化疗后 durvalumab 治疗 IIIA-N2 期非小细胞肺癌的结果。
ESMO Open. 2022 Apr;7(2):100410. doi: 10.1016/j.esmoop.2022.100410. Epub 2022 Mar 2.
2
Lymph Node Parameters Predict Adjuvant Chemoradiotherapy Efficacy and Disease-Free Survival in Pathologic N2 Non-Small Cell Lung Cancer.淋巴结参数可预测病理N2期非小细胞肺癌辅助放化疗疗效及无病生存期
Front Oncol. 2021 Sep 17;11:736892. doi: 10.3389/fonc.2021.736892. eCollection 2021.
3
Radiotherapy Dose and Induction Chemotherapy Cycles Are Associated With Prognosis and Toxicity Risk: A Retrospective Study of 227 Patients With Unresectable Stage III Non-Small-Cell Lung Cancer.
放疗剂量和诱导化疗周期与预后和毒性风险相关：227 例不可切除的 III 期非小细胞肺癌患者的回顾性研究。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820951802. doi: 10.1177/1533033820951802.